top 20 specialty pipeline report - health delegates...chimeric antigen receptor t-cell therapy...

8

©2017 Health Delegates. All Rights Reserved. November 2017 Top 20 Specialty Pipeline Report

Upload: others

Post on 12-Aug-2020

2 views

Category:

Documents

0 download

Report

Download

Embed Size (px):

TRANSCRIPT

$Page 1: Top 20 Specialty Pipeline Report - Health Delegates...Chimeric antigen receptor T-cell therapy (CAR-T therapy) for the treatment of patients with relapsed or refractory aggressive$

©2017 Health Delegates. All Rights Reserved.

November 2017Top 20 Specialty Pipeline Report

$Page 2: Top 20 Specialty Pipeline Report - Health Delegates...Chimeric antigen receptor T-cell therapy (CAR-T therapy) for the treatment of patients with relapsed or refractory aggressive$

©2017 Health Delegates. All Rights Reserved.

$Page 3: Top 20 Specialty Pipeline Report - Health Delegates...Chimeric antigen receptor T-cell therapy (CAR-T therapy) for the treatment of patients with relapsed or refractory aggressive$

©2017 Health Delegates. All Rights Reserved.

$Page 4: Top 20 Specialty Pipeline Report - Health Delegates...Chimeric antigen receptor T-cell therapy (CAR-T therapy) for the treatment of patients with relapsed or refractory aggressive$

©2017 Health Delegates. All Rights Reserved.

$Page 5: Top 20 Specialty Pipeline Report - Health Delegates...Chimeric antigen receptor T-cell therapy (CAR-T therapy) for the treatment of patients with relapsed or refractory aggressive$

©2017 Health Delegates. All Rights Reserved.

December 2017Top 20 Specialty Pipeline Report

$Page 6: Top 20 Specialty Pipeline Report - Health Delegates...Chimeric antigen receptor T-cell therapy (CAR-T therapy) for the treatment of patients with relapsed or refractory aggressive$

©2017 Health Delegates. All Rights Reserved.

$Page 7: Top 20 Specialty Pipeline Report - Health Delegates...Chimeric antigen receptor T-cell therapy (CAR-T therapy) for the treatment of patients with relapsed or refractory aggressive$

©2017 Health Delegates. All Rights Reserved.

$Page 8: Top 20 Specialty Pipeline Report - Health Delegates...Chimeric antigen receptor T-cell therapy (CAR-T therapy) for the treatment of patients with relapsed or refractory aggressive$

©2017 Health Delegates. All Rights Reserved.

P1-27 T CELL GENE THERAPY TO ERADICATE DISSEMINATED … · Background: We created “designer T cells” (dTc) by retroviral gene therapy to express chimeric immunoglobulin-T cell

Released, Relapsed, Rehospitalized

Clinical Updates & Issues: Relapsed/Refractory Multiple ... NCCN Beth Faiman.pdf · Relapsed/Refractory Myeloma • Disease‐related factors – Duration of response to initial therapy

Relapsed Myeloma

Improving T cell therapy for relapsed EBV-negative Hodgkin ...clincancerres.aacrjournals.org/content/clincanres/early/2011/09/09/... · Improving T cell therapy for relapsed EBV-negative

Chimeric antigen receptors (CAR). Chimeric antigen receptors (CAR) Chimeric antigen receptors (CAR) are recombinant receptors that provide both antigen-binding

Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019 Cells) Have Long-Term Persistence and Induce Durable Responses in Relapsed, Refractory

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy ... · 2018. 12. 20. · RESEARCH Open Access A phase 1, open-label study of LCAR-B38M, a chimeric

Chimeric Antigen Receptor T - Cell Therapy for B-Cell

Therapy of relapsed ALL

Chimeric Antigen Receptor (CAR) T Cell Therapy: A Cure for

Controlled phage therapy by photothermal ablation of ... · Controlled phage therapy by photothermal ablation of specific bacterial species using gold nanorods targeted by chimeric

Three months after MDMA-assisted therapy, 6% of ......for psychedelic therapy. Three months after MDMA-assisted therapy, 6% of patients had relapsed – compared to 76% of patients

Management of Multiple Myeloma: The Changing Paradigm...Relapsed/Refractory Myeloma Relapsed/refractory multiple myeloma is treatable Patients typically receive multiple lines of therapy

A PHASE 1 STUDY TO EVALUATE CHIMERIC ANTIGEN … · 2021. 6. 7. · Phase 1 Study Design Patients ≥18 years old (KPS ≥60%, ECOG PS≤2) with grade IV GBM with relapsed disease

Advanced Therapy Medicinal Products Project...The project Having led the NHS service development work for the first two chimeric antigen receptor T-cell (CAR T) therapy products in

Advances in chimeric antigen receptor T-cell therapy for B-cell non … · 2021. 7. 13. · REVIEW Open Access Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin

Relapsed Chronic Myeloid Leukemia: new players in targeted therapy

The Future of Chimeric An1gen Receptor T (CAR T) cell ... · The Future of Chimeric An1gen Receptor T (CAR T) cell Therapy in Lymphoma Caron Jacobson MD, MMSc Assistant Professor

CAR T-cell therapy for a relapsed/refractory acute B-cell ... · CAR T-cell therapy. Then, he received lymphodepleting chemotherapy with fludarabine (25 mg/m2) and cyclo-phosphamide

CAR T Cell Therapy - Amazon Web Services · CAR T Cell Therapy Chimeric Antigen Receptor T cell therapy, or CAR T cell therapy, is an immunotherapy approach to treat cancer. Approaches

Humanized Chimeric Receptors in the Therapy of Multiple

Selection and Sequencing Therapy for Relapsed/Refractory CLL

Chimeric Antigen Receptor (CAR) T-Cell Therapy

Chimeric antigen receptors for the adoptive T cell therapy

Hemophilia B Gene Therapy in Mice using a Novel Chimeric ...€¦ · + Proof of concept for CB 2679d-GT . vs . Padua: Collaboration with Vrije University, Brussels + A novel chimeric

Chimeric Antigen Receptor T Cells Directed Against CD19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and

Chimeric Antigen Receptor (CAR) T Cell Therapy Toxicity

Nature Research€¦ · Web viewQuality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer Supplementary material Methods Assessments

Chimeric Antigen Receptor T-cell Therapy

Improving Chimeric Antigen Receptor (CAR) T cell therapy

Miscellaneous Oncology Drugs · disease previously untreated with alpha interferon therapy and in patients 18 years of age and older who have relapsed following alpha interferon therapy